HLS vs. CRDL, CPH, OGI, CWEB, ACB, GUD, SVA, EDT, MDNA, and ONC
Should you be buying HLS Therapeutics stock or one of its competitors? The main competitors of HLS Therapeutics include Cardiol Therapeutics (CRDL), Cipher Pharmaceuticals (CPH), Organigram (OGI), Charlotte's Web (CWEB), Aurora Cannabis (ACB), Knight Therapeutics (GUD), Sernova (SVA), Spectral Medical (EDT), Medicenna Therapeutics (MDNA), and Oncolytics Biotech (ONC). These companies are all part of the "medical" sector.
Cardiol Therapeutics (TSE:CRDL) and HLS Therapeutics (TSE:HLS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their community ranking, dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.
In the previous week, Cardiol Therapeutics had 1 more articles in the media than HLS Therapeutics. MarketBeat recorded 1 mentions for Cardiol Therapeutics and 0 mentions for HLS Therapeutics. HLS Therapeutics' average media sentiment score of 0.00 equaled Cardiol Therapeutics'average media sentiment score.
13.4% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 59.6% of HLS Therapeutics shares are owned by institutional investors. 4.0% of Cardiol Therapeutics shares are owned by company insiders. Comparatively, 0.5% of HLS Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Cardiol Therapeutics has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500. Comparatively, HLS Therapeutics has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500.
HLS Therapeutics has a consensus price target of C$4.58, indicating a potential downside of 1.61%. Given Cardiol Therapeutics' higher probable upside, analysts plainly believe HLS Therapeutics is more favorable than Cardiol Therapeutics.
HLS Therapeutics received 25 more outperform votes than Cardiol Therapeutics when rated by MarketBeat users. Likewise, 70.83% of users gave HLS Therapeutics an outperform vote while only 69.23% of users gave Cardiol Therapeutics an outperform vote.
Cardiol Therapeutics has a net margin of 0.00% compared to Cardiol Therapeutics' net margin of -43.65%. Cardiol Therapeutics' return on equity of -24.69% beat HLS Therapeutics' return on equity.
HLS Therapeutics has higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than HLS Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
HLS Therapeutics beats Cardiol Therapeutics on 10 of the 15 factors compared between the two stocks.
Get HLS Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HLS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
HLS Therapeutics Competitors List
Related Companies and Tools
